Adding a direct acting anti-viral drug to the standard treatment regime for hepatitis C (peginterferon plus ribavirin) significantly increases the cure rate in the most difficult to treat patients, according to US research published online in The Lancet.
The study found adding the experimental protease inhibitor boceprevir nearly doubled the standard regimen’s effectiveness when it was given to people with genotype 1 hepatitis C for 48 weeks.
The two year trial was conducted at 67 sites involving 520 patients in the US, Canada and Europe.
Introducing Nursing Times Learning
Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.
Click on the topics below to get started: